Stomach Cancer – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Stomach Cancer Market Outlook

Thelansis’s “Stomach Cancer Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Stomach Cancer treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Stomach Cancer Overview

Stomach cancer, also known as gastric cancer, is a malignancy that originates from the stomach lining. It is slow-growing cancer and is considered a multifactorial disease. The International Agency for Research on Cancer (IARC) has classified the bacterium Helicobacter pylori (H. pylori) as a carcinogen in humans due to the evidence linking H. pylori infection and an increased risk of gastric cancer. The mechanism by which H. pylori acts as a carcinogen is believed to be indirect, through the induction of gastritis, which can lead to the development of precancerous conditions such as gastric atrophy, metaplasia, and dysplasia. Individuals with certain genetic disorders, such as hereditary diffuse gastric cancer, Peutz-Jeghers syndrome, and familial adenomatous polyposis, have an increased risk of developing stomach cancer. Mutations or deletions in genes such as p53, BRCA2, MSH2, and MLH1 also increase the risk of gastric cancer. The symptoms of stomach cancer can be classified into two stages: early stage and advanced stage. The most common type of stomach cancer is adenocarcinoma, which accounts for approximately 90% of all cases. Other types of stomach cancer include gastric lymphomas, gastrointestinal stromal tumors, and carcinoid tumors. The risk factors for developing stomach cancer include age, gender, H. pylori infection, family history/genetics, race/ethnicity, diet, previous surgery or health conditions, occupational exposure, tobacco and alcohol use, and obesity. The five-year survival rate for individuals diagnosed with stomach cancer is 31.2%.

• The estimated incidence of stomach cancer in the USA is 5.6 per 100,000 individuals.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2022-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: